Gimv (Flanders) launches new life sciences VC platform
At the forefront of the ecosystem
The new ‘Life Sciences platform’ serves as a strong addition to Gimv’s four existing investment platforms: Sustainable Cities, Smart Industries, Consumer and Healthcare. It will enable the company “to build on the strong track record of Gimv in life sciences investments,” comments Gimv CEO Koen Dejonckheere.
The company’s track record includes excellent returns on investments generated by a variety of portfolio companies over four decades, including Flanders-based biopharma firm Ablynx, in which Gimv was a founding investor, and Covagen, a biotech company acquired by Johnson & Johnson.
The new investment platform will strengthen our position at the forefront of the European life sciences ecosystem, which is known the world over for its strong innovation and excellence in developing life-saving therapeutics.
Larger initial investments
In addition, the new platform enables Gimv to further strengthen its capacity to invest in larger “tickets”. Consequently, initial investments going forward will typically amount to between EUR 10 million and EUR 15 million per company.
Aiming to virtually double its current portfolio, Gimv will retain its Series A and B investment strategies with a particular focus on drug development. Other major investment areas include medtech, digital health, life science tools and agri-biotech.
The new platform is an exciting next step for Gimv. We will be able to further focus our work on providing venture capital to companies with promising new therapies.
In the right spot
In Flanders, Gimv has already invested in several leading players from the local life sciences & health ecosystem, including biopharma innovator Ablynx. Want to discover the many other companies and organizations that make Flanders stand out in terms of life sciences & health? Head to Flanders360 or check out our industry overview.